Articles tagged with Cervical Cancer
Researchers at WashU Medicine developed a new approach to combat cervical cancer by targeting the tumor's fuel supply. A combination of radiation and three drugs that cut off glucose metabolism effectively shuts down tumor metabolism, making it vulnerable to treatment.
Researchers found that standard practices for comparing cervical cancer radiation therapy treatments may be misleading. A new mathematical formula could improve outcomes by providing more accurate predictions and personalization of treatment plans.
A new study from the University of Gothenburg suggests that higher education and income are key factors determining whether women participate in cervical screening. The study, which analyzed data from over 581,000 women, found that country of birth was not a significant factor in participation rates.
Researchers found combining blueberry extract with radiation increases treatment effectiveness for late-stage cervical cancer, reducing healthy cell damage by up to 70%. The study's lead author suggests blueberries as a potential radiosensitizer, a non-toxic chemical that enhances cancer cells' responsiveness to radiation therapy.
Research led by Queen Mary University of London predicts a shift in cervical cancer burden from young to older women. Incidence among 50-54 year olds is expected to increase by 50%, while mortality rates are projected to rise by 109% among 60-64 year olds.
Researchers at NUS Cancer Science Institute discovered a molecular pathway in which TIP60 inhibits cancer cell growth by targeting telomerase. This finding offers a new approach to treating various types of cancer triggered by high telomerase levels.
A decade-long study on hundreds of HPV vaccine recipients found the vaccine to be safe and effective in preventing the most virulent strains of the virus. The quadrivalent vaccine was virtually 100% effective in preventing disease in young individuals.
A study found that only 20% of Indonesian women are aware of cervical smears, with even lower rates for mammography. Higher education, household expenditure, and health insurance were associated with increased awareness and participation. Experts call for improved education and access to resources to increase cancer screening rates.
A new study finds that HPV testing is more sensitive than the Pap test for detecting precancerous cells. Cotesting, which combines both methods, identified more cases of treatable cancer but only affected a small number of women.
A new study suggests that HPV vaccination can reduce the number of cervical screens needed from 12 to just three for vaccinated women. The research also recommends seven lifetime screens for unvaccinated women.
A comprehensive study from the Keck School of Medicine of USC found that IUD use is associated with a dramatic decrease in cervical cancer incidence. The analysis included data from 16 high-quality observational studies involving over 12,000 women worldwide.
A new study found significant disparities in survival rates for patients with different types of human papillomavirus (HPV)-associated cancers. The findings highlight the need for improved HPV vaccination, cancer screening, and treatment access to address these disparities.
A study has identified a new strategy to treat HPV-related cancers, targeting the virus's E6 oncoprotein and its interaction with myc protein. This approach could lead to a more specific and less toxic treatment option.
The study found that four fractions of 7 Gy HDR brachytherapy resulted in significantly better tumor control than two 9-Gy fractions, with a higher survival rate for women with stage IIB disease. Severe treatment-related side effects did not differ significantly between treatment arms.
Female cancer survivors face increased risks of preterm birth and small for gestational age infants after diagnosis. Certain cancers, such as cervical, breast, leukemia, brain cancer, and extranodal non-Hodgkin lymphoma, are linked to poorer pregnancy outcomes.
A randomized trial of over 600 patients confirms chemoradiation as the standard treatment for locally advanced cervical cancer, with no improved disease-free survival seen with neoadjuvant chemotherapy followed by surgery. The findings suggest that chemoradiation should remain the standard treatment.
A new study published in LGBT Health suggests that alternative cervical cancer screening methods, such as HPV self-sampling, can increase screening rates among transgender men. The research found that over half of participants preferred HPV self-sampling and had not received a Pap smear within the previous three years.
Researchers have found that human papillomavirus 16 (HPV16) infections can have varying levels of cancer risk due to unique genetic variations. Studies revealed thousands of distinct HPV16 genomes in infected individuals, with some variants linked to increased carcinogenic potential.
The new 9vHPV vaccine targets nine high-risk HPV types, significantly reducing the risk of cervical cancer, genital warts, and HPV-related vulvar and vaginal cancers. The study found that the vaccine is highly effective in preventing HPV infection and disease, with a 97.7% reduction in risk.
A new study published in The Lancet found that the Gardasil 9 vaccine can reduce 90% of cervical cancer cases with long-term effectiveness. The vaccine was tested on over 14,000 women worldwide and showed similar safety profiles to the four-valent HPV vaccine.
A change in cervical cancer screening guidelines led to a decrease in Pap testing and chlamydia testing among young women. Chlamydia testing declined by 26% in females aged 15-19, resulting in lower reported incidence rates for this age group.
Research confirms a positive correlation between HPV vaccination and increased cervical screening rates, contradicting concerns about reduced screening due to reassurance. However, vaccine cost and provider recommendations remain significant barriers to widespread adoption in the US.
A new study found that home-based HPV self-sampling is an acceptable way to participate in cervical cancer screening programs. Most women chose self-sampling due to its convenience, privacy, and reduced embarrassment.
A study of Senegalese women found that HIV-positive women were more likely to acquire human papillomavirus (HPV) infection and have it progress to precancerous lesions. The research highlights the importance of targeted cervical cancer prevention efforts for high-risk HIV-positive populations.
Researchers at Duke University have developed a handheld device for cervical cancer screening that can capture images of the cervix without a speculum or trained professional. The 'pocket colposcope' is designed to be low-cost, accessible, and potentially self-screening.
Around half of women with locally advanced cervical cancer experience symptoms like fatigue, insomnia, and hot flushes after treatment. Younger women are more likely to be affected. Research highlights the need for better recognition and treatment of these under-recognised symptoms.
A new study found that cervical cancer incidence rates among women without a hysterectomy increase with age until 70 and do not begin to decline until 85. Many women over 65 have inadequate screening history, highlighting the need for continued surveillance.
A therapeutic vaccine is being tested to prevent or reduce cervical cancer recurrence in women at high risk. The vaccine has shown promise in extending survival time for patients with recurrent disease, and its safety and efficacy are being evaluated in a phase 3 study.
A new AI-based image detection method has shown promise in screening for cervical cancer, detecting abnormalities with higher sensitivity and specificity than traditional methods. The technique, developed by Lehigh University researchers, could be used to improve early detection and treatment of the disease in resource-poor regions.
A study of California Medicaid recipients with severe mental illness found low cervical cancer screening rates, with only 20.2% screened compared to 42.3% in the general population. Younger women and those from minority groups had higher screening rates, but there was still a significant disparity in cervical cancer development risk.
Researchers found a genetic variant associated with reduced HPV infection and cervical cancer risk in Saudi Arabia. This variant may be more common in populations with lower cervical cancer incidence rates.
The American Society of Clinical Oncology has released a clinical practice guideline on human papillomavirus (HPV) vaccination for the prevention of cervical cancer. The guideline offers evidence-based recommendations for four levels of resource settings, providing guidance to health care providers worldwide.
Dr. Navkiran Shokar is expanding the De Casa En Casa program to provide free cervical cancer screenings and education to rural counties in Texas, aiming to increase screening rates from 63-71% to 82% nationally. The grant will also train local nurses and community health workers to promote awareness of cervical cancer and its symptoms.
A study found that fewer than three out of five women with locally advanced cervical cancer received guideline-based care, with black and Hispanic women receiving lower rates. Despite an increase in guideline-based care over time, disparities persist, highlighting the need for further investigation into barriers to treatment.
Researchers found that cytology was very sensitive and consistent for detecting invasive cervical cancer even in low-resource settings. Cytology may be used to diagnose cervical cancer earlier in women at high risk, leading to improved overall survival from the disease.
A new, multidisciplinary model of cervical cancer care developed by a University of Pennsylvania team in Botswana cut the delay between diagnosis and treatment by more than 50 percent. The model streamlined care and communication between providers, reducing delays in treatment and simplifying the overall process.
Researchers at OIST have developed a novel technique that targets lipid rafts on cancer cell membranes to block migration. The molecule works by physically pinning the cancer cell, causing it to rupture and leading to cell death.
A new special issue of Preventive Medicine analyzes the shift from cytology to HPV testing for cervical cancer screening, citing improved efficiency and accuracy. Experts endorse HPV testing as a better option, but acknowledge the challenges of implementing changes globally.
New research suggests cervical cancer death rates are higher among older and black women in the US, particularly due to exclusion of women who have had hysterectomies. This discrepancy highlights the need for better screening and treatment options for these groups.
Researchers identified novel genomic characteristics of cervical cancer, including cell signaling pathways and human papillomavirus (HPV) infection. The study also found amplification of genes involved in immune responses and potential therapeutic targets.
Analysis of US data from 2002 to 2012 reveals significantly higher cervical cancer mortality rates among black women (77% higher) and white women (47% higher), with disparities increasing over time. Black women's corrected mortality rate is 10.1 per 100,000 women, compared to 5.7 for uncorrected rates.
Researchers identified a new subtype of cervical cancer with distinct genomic pathways, potentially benefiting from alternative treatments. The study found significant differences in tumor characteristics between HPV-active and -inactive subtypes.
A new study reveals that women with advanced kidney disease are at a higher risk of developing cancer, highlighting the importance of targeted screening strategies.
Researchers developed a novel urine test to predict high-risk cervical cancer with 90.9% accuracy using genetic markers from HPV and human cells. The test shows promise as a cost-effective alternative to existing methods, which may be unnecessary in up to 50% of cases.
A report from Merck KGaA and the American Cancer Society highlights that four top cancer causes in women are mostly preventable or can be detected early, leading to more successful treatment. The number of women who will lose their lives to cancer is expected to increase by 57% from 3.5 million in 2012 to 5.5 million by 2030.
A new series published in The Lancet highlights the need for international efforts to end preventable deaths from breast and cervical cancer, particularly in low- and middle-income countries. Cost-effective interventions, such as routine HPV vaccination and cervical screening, can significantly reduce mortality rates if implemented.
A study published in Gynecologic Oncology found that less than half of cervical cancer patients receive standard-of-care treatment, highlighting the need for improved access. Patients who received brachytherapy had better overall survival rates compared to those receiving only two components of SOC.
A new study from Harvard T.H. Chan School of Public Health suggests that less-intensive cervical cancer screening is needed among women who have been vaccinated against human papillomavirus (HPV), as these women face a substantially lower risk of developing cervical cancer.
Researchers have discovered that HPV16's E7 protein can suppress the body's immune response to the virus. This knowledge could lead to new therapies and ways to block cancer suppression of the immune response.
Extending cervical screening intervals for HPV negative women aged 40+ is safe due to low risk of CIN3+, but not recommended for those testing positive for HPV. Tailoring screening to individual risks using HPV test results and age may improve efficiency and optimal prevention.
A study by LSU Health New Orleans found that people with cervical cancer history consumed significantly more sugar-sweetened beverages, while younger, male, black individuals with high sugar intake were also at higher risk. The researchers recommend targeting lower socio-economic status and young males in intervention programs to reduc...
A new fruit fly model mimics HPV-induced cancer, allowing scientists to understand the underlying mechanism and identify potential drug targets. The model reveals essential roles for Magi and the insulin receptor in E6-driven malignancy.
A new study from the University of Illinois confirms a link between Pap smear screenings and a lower risk of developing cervical cancer in women over age 65. The researchers found that women in this age group were 36% less likely to have had a Pap test, resulting in a 52% reduced risk of malignant cervical cancer.
The American Cancer Society has endorsed HPV vaccination recommendations from the CDC, recommending routine vaccination of all children at age 11 or 12. Vaccination is also recommended for females ages 13 to 26 and males aged 13 to 21 who have not been vaccinated previously or completed the 3-dose series.
A new study published in the Canadian Medical Association Journal found that HPV vaccination programs can reduce cervical cell anomalies in young women. The study showed that 3-dose HPV vaccination has demonstrated early benefits against high-grade cervical abnormalities, which are more likely to progress to cervical cancer.
A new study reveals that welcoming healthcare environments and minor form modifications can increase cervical cancer screening among lesbian, bisexual, and queer women. Routine screeners reported more welcome experiences and less discrimination than nonroutine screeners.
Women with a history of severe cervical intraepithelial neoplasia have an increased risk of developing anal, vulvar, and vaginal cancer, according to a recent study. The study found that women with CIN3 were 4.2 times more likely to develop anal cancer, four times more likely to develop vulvar cancer, and 17 times more likely to develo...
A study found that women with systemic lupus erythematosus (SLE) have a doubled risk of pre-malignant cervical changes and potentially an increased risk of cervical cancer compared to the general female population. Regular cervical screening is crucial for women with SLE, regardless of treatment
Researchers have developed a method to identify HPV infections using self-collected vaginal swabs, which provides accurate results similar to clinician-collected cervical specimens. This technology enables same-day screening and treatment, critical for preventing premature deaths from HPV-associated cancers in low-income countries.
A new study finds HPV vaccination is expected to reduce cancer burden across all racial/ethnic groups, with some disparities persisting despite high vaccine uptake. The study suggests that efforts to improve vaccine uptake must be accompanied by efforts to address access issues for screening and timely diagnoses.